# Azitra Inc. (AZTR)

**Exchange:** NYSE  
**Sector:** Healthcare  
**Market cap:** $1M  
**Price:** $0.22 (-7.33%)

> Azitra Inc. is a clinical-stage biotechnology company that focuses on harnessing the therapeutic potential of the human microbiome. The company is dedicated to developing microbiome-based treatments to address dermatological conditions and improve skin health. Azitra leverages its proprietary platform to design therapies that utilize commensal microbiota, which are the naturally occurring bacteria on human skin, for combating various skin diseases. By targeting skin-associated microbiomes, Azitra aims to create safe and effective treatment options for conditions that may not respond well to conventional treatments. Its innovative approach positions Azitra in the emerging field of microbiome therapy, impacting healthcare and dermatology industries. With its specialized focus, Azitra plays a significant role in advancing biotechnology innovations and contributing to the evolving narrative of precision medicine and personalized healthcare.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | — | — | -$11M | -$11M | — |
| 2024 | $7,500 | — | -$11M | -$9M | — |
| 2023 | $686,000 | — | -$7M | -$11M | — |
| 2022 | $284,000 | — | -$9M | -$11M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $5M | $1M | $4M | $2M | — |
| 2024 | $7M | $2M | $6M | $5M | — |
| 2023 | $5M | $2M | $3M | $2M | — |
| 2022 | $7M | $10M | -$36M | $3M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$11M | $24,213 | -$11M |
| 2024 | -$10M | $8,569 | -$10M |
| 2023 | -$7M | $26,544 | -$7M |
| 2022 | -$8M | $33,101 | -$8M |

Source: [CompaniesByCap](https://companiesbycap.com/company/AZTR)